3D Printed Paracetamol Tablets Have Big Implications for Personalized Medicine

Share this Article

Drugs affect everyone differently. That’s why it’s so hard to find the right medication and right dosage to treat people with depression, for example, or why certain people don’t seem to get much relief from painkillers. That’s why the prospect of 3D printed medication is so exciting. Companies like FabRx are working to create medicines with personalized doses through 3D printing. Not only does 3D printing allow for different medications to be combined in one dose, but, as a new study shows, dosages can also be customized to suit people with different metabolic rates. The study, entitled “Extrusion 3D Printing of Paracetamol Tablets from a Single Formulation with Tunable Release Profiles Through Control of Tablet Geometry,” was written by a group of researchers from the University of Nottingham and GlaxoSmithKline.

“Personalised medicine is defined as a customization of health care to individual patients through linking diagnostics and treatments with genetic testing and emerging technologies such as proteomics and metabolomics analysis,” the researchers state. “The main advantages of this approach are to increase the effectiveness of the prescribed treatment regimen and to minimise their adverse effects such as those linked to overdosing of drugs with a narrow therapeutic index such as digoxin and anti-clotting agents.”

Paracetamol, or acetaminophen, is one of the most commonly used over-the-counter painkillers, so the researchers selected it as the subject for their proof of concept study. Work has been done before using FDM 3D printing to formulate paracetamol tablets, they note, but the high extrusion temperature limits the potential active ingredients to only heat-stable ones. Other methods like SLA and ink-jet printing use excipients that are not generally recognized as safe, however, so FDM was chosen for the study.

A regenHU 3D bioprinter was used to print paracetamol into three different tablet geometries – solid, ring and mesh. The outer dimensions of the tablets were kept in the same oval shape, but the inner geometries were varied, as were the number of layers. The weights of the tablets were also kept consistent by varying their heights. The tablet surface area influenced the speed of the drug release – for example, with the mesh tablets, 70% of the drug was released within the first 15 minutes, while 25% was released from the ring tablets and 12% from the solid tablets in the same period of time.

Notably, each of the tablets contained the same dosage of paracetamol, but the different release rates meant that they would affect people in different ways. These release rates could, therefore, be tailored to specific patients’ metabolisms for the most effective treatment.

“The demonstrated ability to use a single unmodified formulation to achieve defined release profiles presents opportunities to optimise or personalise medicines during formulation development and in clinical use,” the researchers explain. “For example, relatively straightforward personalization of medicines would be possible for individuals with different metabolism rates due to their genetic makeup for certain drugs and hence could address issues where people who metabolise drugs slowly may accumulate a toxic level of a drug in the body or in others who process a drug quickly and never have high enough drug concentrations to be effective.”

Any drug is dangerous when taken in too-high doses, but some people tend to go overboard with painkillers such as paracetamol, because, as the researchers point out, they metabolize the drugs too quickly for them to be effective and thus think that more is better. More is toxic, in fact, but programming drugs so that their release rates are tailored to each individual’s metabolism means that the same dosage can be taken by different people and still have the proper effect on each one.

If this study could be applied to painkillers only, it would still be big news, but its potential goes beyond just paracetamol. Adverse effects could be minimized from drugs such as anticoagulants and antidepressants, even as they are tailored to be more effective to each individual patient. The prospect of personalized medicine through 3D printing has a lot of promise; one day we may look back on our current “one dosage fits all” standard as primitive medicine.

Authors of the paper include Shaban A. Khaled, Morgan R. Alexander, Derek J. Irvine, Ricky D. Wildman, Martin J. Wallace, Sonja Sharpe, Jae Yoo and Clive J. Roberts.

Discuss this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.

 

Share this Article


Recent News

3D Printing Webinar and Virtual Event Roundup: April 17, 2021

MX3D Receives €2.25M to Commercialize Metal 3D Printing Welding Robots



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

JEOL Unveils New Electron Beam Metal 3D Printer

The metal 3D printing industry is experiencing serious waves. If it isn’t new entrants introducing unprecedented quality, then it’s stalwarts unveiling unprecedented numbers of lasers, while bound metal printing begins...

Featured

VELO3D Going Public Will Take Metal Powder Bed Fusion to New Territory

Over the last six months, the additive manufacturing industry has been riding a wave not seen in a decade. In March, the rumors that VELO3D—one of the youngest companies in...

Dream 3D Printing Mergers & Acquisitions: What if Henkel Acquired…

Inspired in part by the SPAC mergers of VELO3D with Jaws, Markforged with one, and Rocket Lab with Vector Acquisition Corporation, as well as the acquisition of EnvisionTEC by Desktop Metal, and...

Featured

Q4 2020 Market Data from SmarTech Analysis Signals Rebounding Metal 3D Printing Segment

SmarTech Analysis, the leading market research firm for the additive manufacturing (AM) industry, has published its latest data for its “AM Market Data Service”. This covers Q4 and the complete...


Shop

View our broad assortment of in house and third party products.